Issued on behalf of Oncolytics Biotech Inc. "We're hitting critical milestones that validate our progress and set the stage for what we believe will be an exciting year," said Wayne Pisano, Interim ...
Biotech continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s ...
USA News GroupNews Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI ...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...
Oncolytics (ONCY) reported on progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s potential in ...
Oncolytics Biotech Inc shares T.ONC are trading unchanged at $1.07.
SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...
Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback